Home > Insider Trading > Filing (0001127602-23-010081)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1145197	Insulet Corp	PODD	Surgical & Medical Instruments & Apparatus (3841)	043523891

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1665678	Charles Alpuche	C/O Insulet Corporation 100 Nagog Park Acton MA 01720	Advisor	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-03-13	23,401	$31.21	68,985	No	4	M	Direct
Common Stock	Disposition	2023-03-13	23,401	$305.15	45,584	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2023-03-13	23,401	$0.00	23,401	$31.21

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
12,347		2026-02-03	No	4	M	Direct

Footnotes

The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $302.98 to $307.17. Specifically: 8,975 shares were sold in the range of $302.98 to $303.98, with a weighted average share price of $303.60; 1,100 shares were sold in the range of $304.01 to $304.29, with a weighted average share price of $304.08; 7,524 shares were sold in the range of $305.35 to $306.35, with a weighted average share price of $305.94;
Footnote continued: and 5802 shares were sold in the range of $306.41 to $307.17, with a weighted average share price of $306.74. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
This option is subject to a four-year vesting period, with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment.